3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
39
Brain Neoplasms
17
Astrocytoma
16
Central Nervous System Neoplasms
9
Oligodendroglioma
8
Gliosarcoma
8
Melanoma
7
Glioma
7
Neoplasms
5
Recurrence
4
Neoplasm Metastasis
3
Neuroblastoma
2
Ganglioneuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Choroid Plexus Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdoid Tumor
1
Rare Diseases
1
Optic Nerve Glioma
1
Neurotoxicity Syndromes
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Neuroepithelial
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Melanoma, Cutaneous Malignant
1
Interventions
Lenalidomide
3
capivasertib
2
Bortezomib
2
tivozanib
1
Zoledronic Acid
1
Vitamin D
1
Temozolomide
1
Radiotherapy
1
Nivolumab
1
Gemcitabine
1
Fulvestrant
1
Etoposide
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Disease Progression
×
Temozolomide
×
Clear all
NCT02761070
2023-03-08
RE-GEND
Kyorin University
Phase 3
Unknown
146 enrolled